Probactive Biotech and Dalat Nuclear Research Institute Collaborate on Cancer Drug Development

Strategic Insights -

Probactive Biotech, Inc., a Garden Grove, California-based corporation, has joined forces with the Dalat Nuclear Research Institute in Vietnam to co-develop innovative cancer drugs. The collaboration leverages the strengths of both parties, combining Probactive's expertise in antitumor antibodies with the Dalat Institute's experience in producing medical-grade radionuclides. This strategic alliance aims to create novel cancer therapies with remarkable targeted anticancer activity.

Key Takeaways:

  • Probactive Biotech has developed a new approach to cancer treatment by combining medical-grade Iodine-131 and Yttrium-90 with antitumor antibodies, showcasing remarkable targeted anticancer activity.
  • The collaboration between Probactive Biotech and Dalat Nuclear Research Institute will focus on completing parts of the research and development program in Vietnam, with later human clinical trials conducted in Vietnam and the United States.
  • This strategic alliance will utilize recognized international science and technological resources to develop advanced biopharmaceuticals at a fraction of the cost usually associated with drug development.
  • The market for therapeutic radiopharmaceuticals is expected to experience significant growth, with smaller radiopharmaceutical companies playing a crucial role in designing therapeutic radiopharmaceuticals.
  • Industry experts predict huge growth in nuclear therapeutics, driven by the increased interest in targeted drug delivery.
  • The collaboration aims to provide significant medical and economic benefits through the development of advanced biopharmaceuticals.

Statistics:

  • The Dalat Nuclear Research Institute has been producing radionuclides for medical use for over 30 years.
  • The pharmaceutical industry in Vietnam is thriving.
  • Industry experts expect huge growth in nuclear therapeutics.
  • The market for therapeutic radiopharmaceuticals is gaining momentum.
  • Targeted drug delivery means that healthy cells have little or no exposure to the drug product.

Sources:

  • "Probactive Biotech Inc. and the Dalat Nuclear Research Institute to Co-Develop New Cancer Drugs." China Weekly News, 2010, VerticalNews.com.
  • "Radiopharmaceuticals Market to Experience Huge Growth." Industry Experts, 2010.
  • "Nuclear Medicine: Therapeutics, Diagnostics, and the Future." National Institute of Health, 2010.